Pages that link to "Q36812669"
The following pages link to Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. (Q36812669):
Displaying 19 items.
- PCSK9 and Atherosclerosis - Lipids and Beyond (Q33675963) (← links)
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering (Q34536594) (← links)
- PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans (Q38652329) (← links)
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia (Q38796312) (← links)
- Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation (Q40201352) (← links)
- Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins (Q46347201) (← links)
- Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. (Q47143670) (← links)
- Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. (Q48209248) (← links)
- Editorial highlights from Cardiovascular Research (Q49549470) (← links)
- Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model (Q49634837) (← links)
- Clinical and translational science in cardiovascular research: highlights from the American Heart Association Scientific Sessions 2017: Changing view on the concept of cardiovascular risk and blood pressure targets (Q50089724) (← links)
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation. (Q51741649) (← links)
- Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels. (Q51766347) (← links)
- PCSK9: From Basic Science Discoveries to Clinical Trials. (Q54631590) (← links)
- Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials (Q57024979) (← links)
- The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases (Q60955111) (← links)
- Hydrogen sulfide inhibits PCSK9 expression through the PI3K/Akt‑SREBP‑2 signaling pathway to influence lipid metabolism in HepG2 cells (Q64078914) (← links)
- A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α (Q89717389) (← links)
- Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes (Q90310093) (← links)